Mitsubishi Tanabe Joins Certara’s Simcyp Consortium
Certara announces the addition of Mitsubishi Tanabe to its Simcyp Consortium as the group’s 34th biopharmaceutical company.
Certara announces the addition of Mitsubishi Tanabe to its Simcyp Consortium as the group’s 34th biopharmaceutical company. Mitsubishi Tanabe has also licensed its proprietary Simcyp Population-based Simulator, which enables companies to study drug activity in virtual patients.
Read the full release
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- Everything to Know About FDA’s Push Towards Radical Transparency in 2025
September 17th 2025
- IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
September 17th 2025
- Managing Background Therapies in the NIMBLE Phase III Trial
September 17th 2025
- Generative AI Transforms Clinical Study Report Development
September 16th 2025